Browsing by Author "Soto, N"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
- ItemOncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma(LIPPINCOTT WILLIAMS & WILKINS, 2003) Fuentealba, C; Pinto, D; Ballesteros, F; Pacheco, D; Boettiger, O; Soto, N; Fernandez, W; Gabler, F; Gonzales, G; Reginato, AJWe report a patient with a nasal hemangiopericytoma associated with an oncogenic hypophosphartemic osteomalacia (OHO). This syndrome results from tumor products that decrease renal tubular phosphate resorption, leading to the osteomalacia. This patient presented with classic bone manifestations of osteomalacia and a nasal tumor. Laboratory studies performed before the first resection of the tumor included normal serum calcium, hypophosphatemia due to decreased tubular reabsorption of phosphate, and an undetectable serum 1,25 dihydroxy vitamin D level. Serum parathormone level was normal. Anterior iliac crest bone biopsy showed characteristic signs of osteomalacia that included increased osteoid and delayed mineralization. A partial resection of the nasal tumor was performed. After the first surgery the patient showed detectable serum level of 1,25 dihydroxy vitamin D, and transient normalization of the tubular reabsorption of phosphate. The patient was also treated with phosphate supplements and vitamin D with transient control of her clinical manifestations and improvement of the radiographic signs of osteomalacia.
- ItemStriving to manage Patagonia guanacos for sustained use in the grazing agroecosystems of southern Chile(1997) Franklin, WL; Bas, F; Bonacic Salas, Cristian; Cunazza, C; Soto, N
- ItemSuccessful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil-induced acute hepatic failure(MARY ANN LIEBERT, INC, 2004) Brusco, F; Gonzalez, G; Soto, N; Arteaga, EAcute hepatic failure is a rare and potentially lethal complication of propylthiouracil (PTU) use for hyperthyroidism. We present a 20-year-old woman with Basedow-Graves' disease who developed PTU-induced fulminant hepatitis, which progressed to acute hepatic failure with grade III hepatic encephalopathy. Laboratory evaluation ruled out the most common causes of fulminant hepatitis. We treated her hyperthyroidism with amiodarone (average daily dose, 200 mg) for 3 weeks, achieving rapid and persistent euthyroidism, (triiodothyronine [T-3] levels ranged between 64 and 109 ng/dL) without side effects. Amiodarone treatment did not abolish the thyroid radioactive iodine uptake (RAIU), allowing for subsequent treatment with radioactive iodine. The clinical course was favorable and the patient achieved full hepatic recovery 3 months after the hepatic failure was detected. After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU-induced fulminant hepatitis.